If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-16. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Applications == Pumps that use oil either as their working fluid (diffusion pumps), or as their lubricant (mechanical rotary pumps), are often the sources of contamination in vacuum systems. Placing a cold trap at the mouth of such a pump greatly lowers the risk that oil vapours will backstream into the cavity. Cold traps can also be used for experiments involving vacuum lines such as small-scale very low temperature distillations/condensations. This is accomplished through the use of a coolant such as liquid nitrogen or a freezing mixture of dry ice in acetone or a similar solvent with a low melting point. Liquid nitrogen is only used when dry ice or other cryogenic approaches will not condense the desired gasses since liquid nitrogen will also condense oxygen. Any oxygen gas content in the vacuum line or any leak in the vacuum line will result in liquid oxygen mixed with the target vapors, often with explosive results. When performed on a larger scale, this technique is called freeze-drying, and the cold trap is referred to as the condenser. Cold traps are also used in cryopump systems to generate hard vacua by condensing the major constituents of the atmosphere (nitrogen, oxygen, carbon dioxide and water) into their liquid or solid forms. An igloo or other snow bivouac may exploit the same principle – confinement of denser cool air within an impermeable lower volume – to reduce cold air reaching the occupants through use of a sump or cill around a raised sleeping platform within.
Broadcasting is the one-way transmission of information from a transmitter to receivers belonging to a public audience. Since the radio waves become weaker with distance, a broadcasting station can only be received within a limited distance of its transmitter. Systems that broadcast from satellites can generally be received over an entire country or continent. Older terrestrial radio and television are paid for by commercial advertising or governments. In subscription systems like satellite television and satellite radio the customer pays a monthly fee. In these systems, the radio signal is encrypted and can only be decrypted by the receiver, which is controlled by the company and can be deactivated if the customer does not pay. Broadcasting uses several parts of the radio spectrum, depending on the type of signals transmitted and the desired target audience. Longwave and medium wave signals can give reliable coverage of areas several hundred kilometers across, but have a more limited information-carrying capacity and so work best with audio signals (speech and music), and the sound quality can be degraded by radio noise from natural and artificial sources. The shortwave bands have a greater potential range but are more subject to interference by distant stations and varying atmospheric conditions that affect reception. In the very high frequency band, greater than 30 megahertz, the Earth's atmosphere has less of an effect on the range of signals, and line-of-sight propagation becomes the principal mode.
Both hard-wired (cable) and through-water electronic voice communications systems may be used with surface-supplied diving. Wired systems are more popular as there is a physical connection to the diver for gas supply in any case, and adding a cable does not change the handling characteristics of the system. Wired communications systems are more reliable and simpler to maintain than through-water systems.
Defects of red blood cell membrane production (as in hereditary spherocytosis and hereditary elliptocytosis) Defects in hemoglobin production (as in thalassemia, sickle-cell disease and congenital dyserythropoietic anemia) Defective red cell metabolism (as in glucose-6-phosphate dehydrogenase deficiency and pyruvate kinase deficiency) Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterized by complement-induced intravascular hemolytic anemia.
Sources: en.wikipedia.org
There are 37 known isotopes of francium ranging in atomic mass from 197 to 233. Francium has seven metastable nuclear isomers. Francium-223 and francium-221 are the only isotopes that occur in nature, with the former being far more common. Francium-223 is the most stable isotope, with a half-life of 21.8 minutes, and it is highly unlikely that an isotope of francium with a longer half-life will ever be discovered or synthesized. Francium-223 is a fifth product of the uranium-235 decay series as a daughter isotope of actinium-227; thorium-227 is the more common daughter. Francium-223 then decays into radium-223 by beta decay (1.149 MeV decay energy), with a minor (0.006%) alpha decay path to astatine-219 (5.4 MeV decay energy). Francium-221 has a half-life of 4.8 minutes. It is the ninth product of the neptunium decay series as a daughter isotope of actinium-225. Francium-221 then decays into astatine-217 by alpha decay (6.457 MeV decay energy). Although all primordial 237Np is extinct, the neptunium decay series continues to exist naturally in tiny traces due to (n,2n) knockout reactions in natural 238U. Francium-222, with a half-life of 14 minutes, may be produced as a result of the beta decay of natural radon-222; this process has nonetheless not yet been observed, and it is unknown whether this process is energetically possible. The least stable ground state isotope is francium-215, with a half-life of 90 ns: it undergoes a 9.54 MeV alpha decay to astatine-211.
===== Meglitinide ===== Meglitinides are similar to sulfonylureas, as they bind to beta cells in the pancreas, but differ by the site of binding to the intended receptor and the drugs' affinities to the receptor. As a result, they have a shorter duration of action compared to sulfonylureas and require higher blood glucose levels to begin to secrete insulin. Both meglitinides, known as nateglinide and repanglinide, are sold in formulations combined with metformin. A repaglinide/metformin combination is sold as Prandimet, or as its generic equivalent.
ATP : NADH+H+ and ATP : FADH2 ratios during the oxidative phosphorylation appear to be not 3 and 2, but 2.5 and 1.5 respectively. Unlike in the substrate-level phosphorylation, the stoichiometry here is difficult to establish. ATP synthase produces 1 ATP / 3 H+. However the exchange of matrix ATP for cytosolic ADP and Pi (antiport with OH− or symport with H+) mediated by ATP–ADP translocase and phosphate carrier consumes 1 H+ / 1 ATP as a result of regeneration of the transmembrane potential changed during this transfer, so the net ratio is 1 ATP : 4 H+. The mitochondrial electron transport chain proton pump transfers across the inner membrane 10 H+ / 1 NADH+H+ (4 + 2 + 4) or 6 H+ / 1 FADH2 (2 + 4). So the final stoichiometry is 1 NADH+H+ : 10 H+ : 10/4 ATP = 1 NADH+H+ : 2.5 ATP 1 FADH2 : 6 H+ : 6/4 ATP = 1 FADH2 : 1.5 ATP ATP : NADH+H+ coming from glycolysis ratio during the oxidative phosphorylation is 1.5, as for FADH2, if hydrogen atoms (2H++2e−) are transferred from cytosolic NADH+H+ to mitochondrial FAD by the glycerol phosphate shuttle located in the inner mitochondrial membrane. 2.5 in case of malate-aspartate shuttle transferring hydrogen atoms from cytosolic NADH+H+ to mitochondrial NAD+ So finally we have, per molecule of glucose
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.